Company news
Tango Therapeutics, Inc. news in 2022
Tango Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights
November 9, 2022
Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 18, 2022
Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting
October 4, 2022
Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 9, 2022
Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
August 1, 2022
Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
June 26, 2022
Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
June 7, 2022
Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 10, 2022
Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022
May 8, 2022
Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 27, 2022
Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting
March 7, 2022
Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress
March 2, 2022
Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates
January 23, 2022